Minimal within-host dengue models highlight the specific roles of the immune response in primary and secondary dengue infections

Journal of the Royal Society Interface

Volumn 12, Issue 103, 2015, Pages

  Ben Shachar, Rotem ^a   Koelle, Katia ^a,b  

^a DUKE UNIVERSITY   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Cytokine storm; Dengue; Disease severity; Immune response; Mathematical model; Viral dynamics

Indexed keywords

CELLS; CYTOLOGY; DYNAMICS; MATHEMATICAL MODELS; STORMS; T-CELLS;

ADAPTIVE IMMUNE RESPONSE; ANTIBODY-DEPENDENT ENHANCEMENTS; CRITICAL COMPONENT; CYTOKINES; DENGUE; DISEASE SEVERITY; IMMUNE RESPONSE; INNATE IMMUNE RESPONSE;

IMMUNE SYSTEM;

ALPHA INTERFERON; INTERLEUKIN 6; INTERLEUKIN 8; TUMOR NECROSIS FACTOR ALPHA;

ADAPTIVE IMMUNITY; ANTIBODY DEPENDENT ENHANCEMENT; ANTIBODY RESPONSE; ARTICLE; CELLULAR IMMUNITY; CYTOKINE PRODUCTION; CYTOKINE STORM; DENGUE; DISEASE SEVERITY; HOST PATHOGEN INTERACTION; HUMAN; IMMUNE RESPONSE; INNATE IMMUNITY; MATHEMATICAL MODEL; NATURAL KILLER CELL; NONHUMAN; PRIMARY INFECTION; SECONDARY INFECTION; T LYMPHOCYTE; TARGET CELL; VIRAL CLEARANCE; VIREMIA; VIRUS INFECTIVITY; VIRUS LOAD; VIRUS PARTICLE; ANIMAL; BIOLOGICAL MODEL; DENGUE VIRUS; IMMUNOLOGY; PHYSIOLOGY; VIROLOGY;

ANIMALS; DENGUE; DENGUE VIRUS; HOST-PATHOGEN INTERACTIONS; HUMANS; MODELS, IMMUNOLOGICAL; VIREMIA;

EID: 85005932152     PISSN: 17425689     EISSN: 17425662     Source Type: Journal    
DOI: 10.1098/rsif.2014.0886     Document Type: Article

References (77)

1. Bhatt S et al. 2013 The global distribution and burden of dengue. Nature 496, 504-507. (doi:10. 1038/nature12060).
2. Whitehorn J, Simmons CP. 2011 The pathogenesis of dengue. Vaccine 29, 7221-7228. (doi:10.1016/j. vaccine.2011.07.022).
3. Shresta S, Kyle JL, Snider HM, Basavapatna M, Beatty PR, Harris E. 2004 Interferon-dependent immunity is essential for resistance to primary dengue virus infection in mice, whereas T- and B-cell-dependent immunity are less critical. J. Virol. 78, 2701-2710. (doi:10.1128/JVI.78.6. 2701-2710.2004).
4. Prestwood TR, Morar MM, Zellweger RM, Miller R, May MM, Yauch LE, Lada SM, Shresta S. 2012 Gamma interferon (IFN-gamma) receptor restricts systemic dengue virus replication and prevents paralysis in IFNalpha/beta receptor-deficient mice. J. Virol. 86, 12561-12570. (doi:10.1128/JVI.06743-11).
5. Kliks SC, Nisalak A, Brandt WE, Wahl L, Burke DS. 1989 Antibody-dependent enhancement of dengue virus growth in human monocytes as a risk factor for dengue hemorrhagic fever. Am. J. Trop. Med. Hyg. 40, 444-451.
6. Morens DM, Halstead SB. 1990 Measurement of antibody-dependent infection enhancement of four dengue virus serotypes by monoclonal and polyclonal antibodies. J. Gen. Virol. 71, 2909-2914. (doi:10.1099/0022-1317-71-12-2909).
7. Rothman AL. 2011 Immunity to dengue virus: A tale of original antigenic sin and tropical cytokine storms. Nat. Rev. Immunol. 11, 532-543. (doi:10. 1038/nri3014).
8. Rothman AL. 2004 Dengue: defining protective versus pathologic immunity. J. Clin. Invest. 113, 946-951. (doi:10.1172/JCI21512).
9. Tricou V, Minh NN, Farrar J, Tran HT, Simmons CP. 2011 Kinetics of viremia and NS1 anti genemia are shaped by immune status and virus serotype in adults with dengue. PLoS Negl. Trop. Dis. 5, e1309. (doi:10.1371/journal.pntd.0001309).
10. Libraty DH et al. 2002 Differing influences of virus burden and immune activation on disease severity in secondary dengue-3 virus infections. J. Infect. Dis. 185, 1213-1221. (doi:10.1086/340365).
11. Vaughn DW et al. 2000 Dengue viremia titer, antibody response pattern, and virus serotype correlate with disease severity. J. Infect. Dis. 181, 2-9. (doi:10.1086/315215).
12. Green S, Pichyangkul S, Vaughn DW, Kalayanarooj S, Nimmannitya S, Nisalak A, Kurane I, Rothman AL, Ennis FA. 1999 Early CD69 expression on peripheral blood lymphocytes from children with dengue hemorrhagic fever. J. Infect. Dis. 180, 1429-1435. (doi:10.1086/315072).
13. Tisoncik JR, Korth MJ, Simmons CP, Farrar J, Martin TR, Katze MG. 2012 Into the eye of the cytokine storm. Microbiol. Mol. Biol. Rev. 76, 16-32. (doi:10. 1128/MMBR.05015-11).
14. Martina BEE, Koraka P, Osterhaus ADME. 2009 Dengue virus pathogenesis: An integrated view. Clin. Microbiol. Rev. 22, 564-581. (doi:10.1128/CMR.00035-09).
15. Perelson AS. 2002 Modelling viral and immune system dynamics. Nat. Rev. Immunol. 2, 28-36. (doi:10.1038/nri700).
16. Perelson A, Nelson PW. 1999 Mathematical analysis of HIV-1 dynamics in vivo. SIAM Rev. 41, 3-44. (doi:10.1137/S0036144598335107).
17. Neumann AU, Lam NP, Dahari H, Gretch D, TE W, Layden TJ, Perelson AS. 1998 Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science 282, 103-107. (doi:10.1126/science.282.5386.103).
18. Dobrovolny HM, Reddy MB, Kamal MA, Rayner CR, Beauchemin CAA. 2013 Assessing mathematical models of influenza infections using features of the immune response. PLoS ONE 8, e57088. (doi:10. 1371/journal.pone.0057088).
19. Handel A, Longini Jr IM, Antia R. 2010 Towards a quantitative understanding of the within-host dynamics of influenza a infections. J. R. Soc. Interface 7, 35-47. (doi:10.1098/rsif.2009.0067).
20. Saenz RA et al. 2010 Dynamics of influenza virus infection and pathology. J. Virol. 84, 3974-3983. (doi:10.1128/JVI.02078-09).
21. Pawelek KA, Huynh GT, Quinlivan M, Cullinane A, Rong L, Perelson AS. 2012 Modeling within-host dynamics of influenza virus infection including immune responses. PLoS Comput. Biol. 8, e1002588. (doi:10.1371/journal.pcbi.1002588).
22. Canini L, Carrat F. 2011 Population modeling of influenza A/H1N1 virus kinetics and symptom dynamics. J. Virol. 85, 2764-2770. (doi:10.1128/JVI.01318-10).
23. Nuraini N, Tasman H, Soewono E, Sidarto KA. 2009 A with-in host dengue infection model with immune response. Math. Comp. Model. 41, 1148-1155. (doi:10.1016/j.mcm.2008.06.016).
24. Ansari NA, Hesaaraki M. 2012 A within host dengue infection model with immune response and Beddington-De Angelis incidence rate. Appl. Math. 3, 177-184. (doi:10.4236/am.2012.32028).
25. Clapham HE, Tricou V, Van Vinh Chau N, Simmons CP, Ferguson NM. 2014 Within-host viral dynamics of dengue serotype 1 infection. J. R. Soc. Interface 11, 20140094. (doi:10.1098/rsif.2014.0094).
26. Gujarati TP, Ambika G. 2014 Virus antibody dynamics in primary and secondary dengue infections. J. Math. Biol. 69, 1773-1800. (doi:10. 1007/s00285-013-0749-4).
27. Dung NTP et al. 2010 Timing of CD8 T cell responses in relation to commencement of capillary leakage in children with dengue. J. Immunol. 184, 7281-7287. (doi:10.4049/jimmunol.0903262).
28. Weiskopf D et al. 2013 Comprehensive analysis of dengue virus-specific responses supports an HLA linked protective role for CD8 T cells. Proc. Natl Acad. Sci. USA 110, E2046-E2053. (doi:10.1073/pnas.1305227110).
29. Duyen HTL et al. 2011 Kinetics of plasma viremia and soluble nonstructural protein 1 concentrations in dengue: differential effects according to serotype and immune status. J. Infect. Dis. 203, 1292-1300. (doi:10.1093/infdis/jir014).
30. Butthep P, Chunhakan S, Yoksan S, Tangnararatchakit K, Chuansumrit A. 2012 Alteration of cytokines and chemokines during febrile episodes associated with endothelial cell damage and plasma leakage in dengue hemorrhagic fever. Pediatr. Infect. Dis. J. 31, e232-e238. (doi:10.1097/INF.0b013e31826fd456).
31. Hober D et al. 1993 Serum levels of tumor necrosis factor-alpha (TNF-a), interleukin-6 (IL-6), and interleukin-1 b (IL-1 b) in dengue-infected patients. Am. J. Trop. Med. Hyg. 48, 324-331.
32. Restrepo BN, Isaza DM, Salazar CL, Ramieérez R, Ospina M, Alvarez LG. 2008 Serum levels of interleukin-6, tumor necrosis factor-alpha and interferon-gamma in infants with and without dengue. Rev. Soc. Bras. Med. Trop. 41, 6-10. (doi:10.1590/S0037-86822008000100002).
33. Rathakrishnan A, Wang SM, Hu Y, Khan AM, Ponnampalavanar S, Lum LCS, Manikam R, Sekaran SD. 2012 Cytokine expression profile of dengue patients at different phases of illness. PLoS ONE 7, e52215. (doi:10.1371/journal.pone.0052215).
34. Kumar Y, Liang C, Bo Z, Rajapakse JC, Ooi EE, Tannenbaum SR. 2012 Serum proteome and cytokine analysis in a longitudinal cohort of adults with primary dengue infection reveals predictive markers of DHF. PLoS Negl. Trop. Dis. 6, e1887. (doi:10.1371/journal.pntd.0001887).
35. Chan M, Johansson MA. 2012 The incubation periods of dengue viruses. PLoS ONE 7, e50972. (doi:10.1371/journal.pone.0050972).
36. Baccam P, Beauchemin C, Macken CA, Hayden FG, Perelson AS. 2006 Kinetics of influenza A virus infection in humans. J. Virol. 80, 7590-7599. (doi:10.1128/JVI.01623-05).
37. Sithisarn P, Suksanpaisan L, Thepparit C, Smith DR. 2003 Behavior of the dengue virus in solution. J. Med. Virol. 71, 532-539. (doi:10.1002/jmv.10520).
38. Fernandez-Garcia M-D, Mazzon M, Jacobs M, Amara A. 2009 Pathogenesis of flavivirus infections: using and abusing the host cell. Cell Host Microbe 5, 318-328. (doi:10.1016/j.chom.2009.04.001).
39. Green AM, Beatty PR, Hadjilaou A, Harris E. 2014 Innate immunity to dengue virus infection and subversion of antiviral responses. J. Mol. Biol. 426, 1148-1160. (doi:10.1016/j.jmb.2013.11.023).
40. Chen Y-C, Wang S-Y. 2002 Activation of terminally differentiated human monocytes/macrophages by dengue virus: productive infection, hierarchical production of innate cytokines and chemokines, and the synergistic effect of lipopolysaccharide. J. Virol. 76, 9877-9887. (doi:10.1128/JVI.76.19.9877- 9887.2002).
41. Petitdemange C, Wauquier N, Rey J, Hervier B, Leroy E, Vieillard V. 2014 Control of acute dengue virus infection by natural killer cells. Front. Immunol. 5, 209. (doi:10.3389/fimmu.2014.00209).
42. Yokoyama WM, Kim S, French AR. 2004 The dynamic life of natural killer cells. Annu. Rev. Immunol. 22, 405-429. (doi:10.1146/annurev. immunol.22.012703.104711).
43. Kurane I, Innis BL, Nimmannitya S, Nisalak A, Meager A, Janus J, Ennis FA. 1991 Activation of T lymphocytes in dengue virus infections. High levels of soluble interleukin 2 receptor, soluble CD4, soluble CD8, interleukin 2, and interferon-gamma in sera of children with dengue. J. Clin. Invest. 88, 1473-1480. (doi:10.1172/JCI115457).
44. Tang Y et al. 2010 Both viremia and cytokine levels associate with the lack of severe disease in secondary dengue 1 infection among adult Chinese patients. PLoS ONE 5, e15631. (doi:10.1371/journal. pone.0015631).
45. Azeredo EL, De Oliveira-Pinto LM, Zagne SM, Cerqueira DIS, Nogueira RMR, Kubelka CF. 2006 NK cells, displaying early activation, cytotoxicity and adhesion molecules, are associated with mild dengue disease. Clin. Exp. Immunol. 143, 345-356. (doi:10.1111/j.1365-2249.2006.02996.x).
46. Navarro-Saeénchez E, Desprès P, Cedillo-Barroeén L. 2005 Innate immune responses to dengue virus. Arch. Med. Res. 36, 425-435. (doi:10.1016/j. arcmed.2005.04.007).
47. Shechter Y, Preciado-Patt L, Schreiber G, Fridkin M. 2001 Prolonging the half-life of human inter feronalpha 2 in circulation: design, preparation, and analysis of (2-sulfo-9-fluorenylmethoxycarbonyl)7- interferon-alpha 2. Proc. Natl Acad. Sci. USA 98, 1212-1217. (doi:10.1073/pnas.98.3.1212).
48. Wang W-K et al. 2006 Slower rates of clearance of viral load and virus-containing immune complexes in patients with dengue hemorrhagic fever. Clin. Infect. Dis. 43, 1023-1030. (doi:10.1086/507635).
49. Zhang Y et al. 2007 In vivo kinetics of human natural killer cells: The effects of ageing and acute and chronic viral infection. Immunology 121, 258-265. (doi:10.1111/j.1365-2567.2007.02573.x).
50. Reperant LA, Kuiken T, Grenfell BT, Osterhaus ADME, Dobson AP. 2012 Linking influenza virus tissue tropism to population-level reproductive fitness. PLoS ONE 7, e43115. (doi:10.1371/journal.pone. 0043115).
51. Nowak M, May R. 2000 Virus dynamics: mathematical principles of immunology and virology. Oxford, UK: Oxford University Press.
52. Friberg H et al. 2011 Cross-reactivity and expansion of dengue-specific T cells during acute primary and secondary infections in humans. Sci. Rep. 1, 51. (doi:10.1038/srep00051).
53. Guzman MG, Alvarez M, Halstead SB. 2013 Secondary infection as a risk factor for dengue hemorrhagic fever/dengue shock syndrome: An historical perspective and role of anti body dependent enhancement of infection. Arch. Virol. 158, 1445-1459. (doi:10.1007/s00705-013-1645-3).
54. Murphy BR, Whitehead SS. 2011 Immune response to dengue virus and prospects for a vaccine. Annu. Rev. Immunol. 29, 587-619. (doi:10.1146/annurevimmunol- 031210-101315).
55. Belz GT, Zhang L, Lay MDH, Kupresanin F, Davenport MP. 2007 Killer T cells regulate antigen presentation for early expansion of memory, but not naive, CD8 T cell. Proc. Natl Acad. Sci. USA 104, 6341-6346. (doi:10.1073/pnas.0609990104).
56. Nguyet MN et al. 2013 Host and viral features of human dengue cases shape the population of infected and infectious Aedes aegypti mosquitoes. Proc. Natl Acad. Sci. USA 110, 9072-9077. (doi:10. 1073/pnas.1303395110).
57. Srikiatkhachorn A, Green S. 2010 Markers of dengue disease severity. Curr. Top. Microbiol. Immunol. 338, 67-82. (doi:10.1007/978-3-642-02215-9-6).
58. Basu A, Chaturvedi UC. 2008 Vascular endothelium: The battlefield of dengue viruses. FEMS Immunol. Med. Microbiol. 53, 287-299. (doi:10.1111/j.1574- 695X.2008.00420.x).
59. Chaturvedi UC, Agarwal R, Elbishbishi EA, Mustafa AS. 2000 Cytokine cascade in dengue hemorrhagic fever: Implications for pathogenesis. FEMS Immunol. Med. Microbiol. 28, 183-188. (doi:10.1111/j.1574- 695X.2000.tb01474.x).
60. Raghupathy R et al. 1998 Elevated levels of IL-8 in dengue hemorrhagic fever. J. Med. Virol. 56, 280-285. (doi:10.1002/(SICI)1096- 9071(199811)56:3<280::AID-JMV18>3.0.CO;2-I).
61. Chakravarti A, Kumaria R. 2006 Circulating levels of tumour necrosis factor-alpha & interferon-gamma in patients with dengue & dengue haemorrhagic fever during an outbreak. Indian J. Med. Res. 123, 25-30.
62. Braga EL, Moura P, Pinto LM, Ignaeécio SR, Oliveira MJ, Cordeiro MT, Kubelka CF. 2001 Detection of circulant tumor necrosis factor-alpha, soluble tumor necrosis factor p75 and interferon-gamma in Brazilian patients with dengue fever and dengue hemorrhagic fever. Mem. Inst. Oswaldo Cruz 96, 229-232. (doi:10.1590/S0074-02762001000200015).
63. Hober D, Delannoy AS, Benyoucef S, De Groote D, Wattreeé P. 1996 High levels of sTNFR p75 and TNFalpha in dengue-infected patients. Micro biol. Immunol. 40, 569-573. (doi:10.1111/j.1348-0421. 1996.tb01110.x).
64. Iyngkaran N, Yadav M, Sinniah M. 1995 Augmented inflammatory cytokines in primary dengue infection progressing to shock. Singapore Med. J. 36, 218-221.
65. Perez AB et al. 2010 Tumor necrosis factor-alpha, transforming growth factor-1, and interleukin-10 gene polymorphisms: Implication in protection or susceptibility to dengue hemorrhagic fever. Hum. Immunol. 71, 1135-1140. (doi:10.1016/j.humimm. 2010.08.004).
66. Mathew A, Rothman AL. 2008 Understanding the contribution of cellular immunity to dengue disease pathogenesis. Immunol. Rev. 225, 300-313. (doi:10.1111/j.1600-065X.2008.00678.x).
67. Rothman AL, Medin CL, Friberg H, Currier JR. 2014 Immunopathogenesis versus protection in dengue virus infections. Curr. Trop. Med. Rep. 1, 13-20. (doi:10.1007/s40475-013-0009-0).
68. Mongkolsapaya J et al. 2003 Original antigenic sin and apoptosis in the pathogenesis of dengue hemorrhagic fever. Nat. Med. 9, 921-927. (doi:10. 1038/nm887).
69. Weiskopf D, Angelo MA, Sidney J, Peters B, Shresta S, Sette A. 2014 Immunodominance changes as a function of the infecting dengue virus serotype and primary versus secondary infection. J. Virol. 88, 11383-11394. (doi:10.1128/JVI.01108-14).
70. Marino S, Hogue IB, Ray CJ, Kirschner DE. 2008 A methodology for performing global uncertainty and sensitivity analysis in systems biology. J. Theor. Biol. 254, 178-196. (doi:10.1016/j.jtbi.2008.04.011).
71. Blower SM, Dowlatabadi H. 1994 Sensitivity and uncertainty analysis of complex models of disease transmission: An HIV model, as an example. Int. Stat. Rev. 62, 229-243. (doi:10.2307/1403510).
72. Biswas HH, Ortega O, Gordon A, Standish K, Balmaseda A, Kuan G, Harris E. 2012 Early clinical features of dengue virus infection in Nicaraguan children: A longitudinal analysis. PLoS Negl. Trop. Dis. 6, e1562. (doi:10.1371/journal.pntd.0001562).
73. Endy TP, Nisalak A, Chunsuttitwat S, Vaughn DW, Green S, Ennis FA, Rothman AL, Libraty DH. 2004 Relationship of preexisting dengue virus (DV) neutralizing antibody levels to viremia and severity of disease in a prospective cohort study of DV infection in Thailand. J. Infect. Dis. 189, 990-1000. (doi:10.1086/382280).
74. Guzmaeén MG, Kourieé G, Valdeeés L, Bravo J, Vaeézquez S, Halstead SB. 2002 Enhanced severity of secondary dengue-2 infections: death rates in 1981 and 1997 Cuban outbreaks. Rev. Panam. Salud Publica 11, 223-227. (doi:10.1590/S1020-49892002000400003).
75. Sabin AB. 1952 Research on dengue during World War II. Am. J. Trop. Med. Hyg. 1, 30-50.
76. Reich NG et al. 2013 Interactions between serotypes of dengue highlight epidemiological impact of cross-immunity. J. R. Soc. Interface 10, 20130414. (doi:10.1098/rsif.2013.0414).
77. Halstead SB, Mahalingam S, Marovich MA, Ubol S, Mosser DM. 2010 Intrinsic antibody-dependent enhancement of microbial infection in macrophages: disease regulation by immune complexes. Lancet Infect. Dis. 10, 712-722. (doi:10.1016/S1473- 3099(10)70166-3).